InMed Pharmaceuticals (INM) Total Non-Current Liabilities (2020 - 2021)
InMed Pharmaceuticals (INM) posted quarterly Total Non-Current Liabilities of $166549.0 for Q1 2021, down 93.04% quarter-over-quarter from $2.4 million in Q4 2020.
InMed Pharmaceuticals (INM) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends
InMed Pharmaceuticals' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $166549.0 for Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 166,549.00 |
| Dec 31, 2020 | 2.39 Mn |